Tasci, E. S. Et Al. 2022. Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4 .

Tasci, E. S., Oyan, B., Sonmez, O., Mutlu, A. U., Atci, M. M., Oner, I., ... Cinkir, H. Y.(2022). Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4.

Tasci, Elif Et Al. "Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study," JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4, 2022

Tasci, Elif S. Et Al. "Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4, 2022

Tasci, E. S. Et Al. (2022) . "Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.4.

@article{article, author={Elif Senocak Tasci Et Al. }, title={Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2022}